Equities research analysts predict that Roivant Sciences Ltd. (NASDAQ:ROIV – Get Rating) will announce $15.41 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Roivant Sciences’ earnings, with the lowest sales estimate coming in at $6.00 million and the highest estimate coming in at $24.83 million. The firm is expected to issue its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that Roivant Sciences will report full year sales of $49.22 million for the current financial year, with estimates ranging from $21.00 million to $70.89 million. For the next year, analysts anticipate that the firm will post sales of $77.13 million, with estimates ranging from $8.40 million to $134.25 million. Zacks’ sales calculations are a mean average based on a survey of research firms that follow Roivant Sciences.
Several equities research analysts have issued reports on ROIV shares. Cantor Fitzgerald started coverage on shares of Roivant Sciences in a report on Friday, April 29th. They issued an “overweight” rating and a $15.00 price target on the stock. Zacks Investment Research lowered shares of Roivant Sciences from a “hold” rating to a “sell” rating in a report on Friday, February 18th. The Goldman Sachs Group lowered their target price on shares of Roivant Sciences from $15.00 to $12.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, SVB Leerink assumed coverage on shares of Roivant Sciences in a report on Monday, May 23rd. They issued an “outperform” rating and a $6.00 target price on the stock. One equities research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $11.86.
In other news, CAO Rakhi Kumar sold 7,281 shares of the company’s stock in a transaction that occurred on Friday, March 25th. The stock was sold at an average price of $5.06, for a total transaction of $36,841.86. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Matthew Gline sold 8,509 shares of the company’s stock in a transaction that occurred on Monday, April 25th. The stock was sold at an average price of $3.84, for a total value of $32,674.56. Following the transaction, the chief executive officer now directly owns 1,404,448 shares in the company, valued at $5,393,080.32. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 660,452 shares of company stock worth $2,969,847.
Large investors have recently made changes to their positions in the business. Northern Trust Corp bought a new position in shares of Roivant Sciences during the 4th quarter worth $1,697,000. InterOcean Capital Group LLC bought a new position in shares of Roivant Sciences during the 4th quarter worth $121,000. Charles Schwab Investment Management Inc. bought a new position in shares of Roivant Sciences during the 4th quarter worth $6,967,000. Renaissance Technologies LLC bought a new position in shares of Roivant Sciences during the 4th quarter worth $335,000. Finally, Geode Capital Management LLC bought a new position in shares of Roivant Sciences during the 4th quarter worth $11,694,000. Hedge funds and other institutional investors own 61.49% of the company’s stock.
About Roivant Sciences (Get Rating)
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia.
- Get a free copy of the StockNews.com research report on Roivant Sciences (ROIV)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.